Company profile
Insight Molecular Diagnostics Inc.
NASDAQ: IMDX · Healthcare · Medical - Diagnostics & Research
#720 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
37DFH 20DQ 46GM 63SS 56
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$1.9M
Rev growth YoY (TTM)
-49.3%
Net income (FY)
-$50.2M
Employees
57
as of 2026-08-14
Market cap
$119.8M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.1M$4.1M2025
Net income-$50.2M-$50.2M2025
Operating income-$51.1M-$51.1M2025
Total assets$25.8M$25.8M2025
Liabilities$57.2M$57.2M2025
Equity-$31.5M-$31.5M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Laboratory Services100%
By geography
UNITED STATES99%
Europe1%
The read
What is Insight Molecular Diagnostics Inc.’s revenue?
Insight Molecular Diagnostics Inc. booked $4.1M in FY2025 revenue, growing 116% year over year — faster than most Healthcare companies we track, at a -1238.5% net margin.
Peers · Healthcare
Arrayit Corporation——ProPhase Labs, Inc.38DComprehensive Healthcare Systems, Inc.42DHemagen Diagnostics, Inc.——CG Oncology Inc.47DCervoMed Inc.42DNeighbors
Davidson →Key facts
CEOJoshua Riggs
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersNashville, TN
ExchangeNASDAQ: IMDX
Employees57
IPO date2015-12-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.